Glaucoma Medications Market
Glaucoma Medications Market Global Industry Assessment & Forecast
- By Indication Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others
- By Drug Class Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others
|2021 - 2028
|2016 - 2020
|Revenue CAGR (2021 - 2028):
|Fastest Growing Region (2022 - 2028)
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
The global Glaucoma Medications market was valued at USD 7.51 Billion in 2020 and is projected to reach USD 10.76 Billion by 2028, growing at a CAGR of 4.6% from 2021 to 2028.
|Historical Data (Actual Data)
|Base Year Data
|Current Year Date
|Projected year data
|Annual Market Size (2028)
|Annual Market Size (2021)
|CAGR (2021 - 2028)
Definition And Overview
The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure below a level that is likely to produce further damage to the nerve.
This report provides an analysis of the Glaucoma Medications market for the historic period of 2016–2019 and forecasts for 2021–2028 while 2020 is considered as a base year for estimations. The report covers exhaustive analysis on the global Glaucoma Medications industry, which includes market trends, drivers, restraints, opportunities, segmental analysis, regional trends, and competitive landscape among others. The report provides a detailed study on various product types and their applications in different industry verticals at the global/regional/country level. This study comprises the market size in terms of revenue for each segment at the global/regional/country level along with a detailed analysis of growth prospects, challenges, and opportunities. Moreover, it covers an extensive competitive landscape covering key players in the industry and their comparative study on the basis of different parameters such as company overview, product portfolio, market revenue, business, and marketing strategies.
The report includes a separate section covering detailed Glaucoma Medications industry analysis based on various macro/micro factors impacting the growth of the market. This section explains various driving factors, restraints/challenges, and opportunities in detail. In addition to that, the same section provides industry analysis based on several strategic marketing tools such as Cost Structure Analysis, Porter’s Five Forces Analysis, Pricing Analysis, SWOT Analysis, PESTLE Analysis, Player Positioning Analysis, Downstream Buyers, List of distributors, and Value Chain Analysis among others.
The rising cases of glaucoma across the globe and new drug developments are expected to fuel the growth of the market during the forecast period.
The technological advancement in treatment of glaucoma, and various pharmaceutical and biotechnological companies are investing in new product development for glaucoma is a factor driving the market.
No pain as well as the lack of symptoms until noticeable vision loss is considered to limit the growth of the glaucoma treatment market in the near future.
COVID-19 Impact Analysis
When the Covid19 pandemic started in China last year it sends its shock waves to countries across the globe. And as the number of cases was on the rise, it enforced the governments across the world to take severe actions like border seals, lockdown, and implementing strict social distancing measures, in order to stop the impending catastrophe. These actions had a dramatic impact on the economy, as the industrialist across the globe were forced to halt their production, leading to supply chain disruptions and impairing of various industries. Thus, plummeting the global markets. However, it is expected that reopening of trade activities, the market will witness steady growth in demand in the coming years. The impact of COVID-19 on the market demand is considered while estimating the current and forecast market size and growth trends for all the regions and countries.
The report provides a completely separate chapter for COVID-19 Impact Analysis. This chapter includes:
o Impact Assessment of COVID-19 Pandemic
o Pre & Post COVID-19 Market Size
o Qualitative analysis on the short term & long-term impact of COVID-19 on the market
o The analysis provides foremost strategies adopted by competitors to minimize the impact of the pandemic on their business activities and scope for future developments.
|Market Size Provided for Years
|Market Size Provided In Terms Of
|Revenue & Volume
|Indication, Drug Class
|North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|The U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, South East Asia, Brazil, Argentina, GCC Countries, and South Africa, among others
|Laboratoires Thea, Actavis, APOTEX, GE Medical, Mylan, Taj Pharmaceuticals, Teva Pharmaceutical, Jamp Pharma, Greenstone, Mint Pharmaceuticals, SANDOZ, Bausch + Lomb, Fresenius, Sun Pharma, Laboratoire Riva, Pfizer, Novartis.
|Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market attractiveness analysis by segments and North America, company market share analysis, and COVID-19 impact analysis
The report delivers an acute breakdown of the market based on various segments such as Indication, Drug Class, , and region. All the segments are studied considering historical and future trends across geographies. All the segments are analyzed based on trends, market size, and forecast, and the data is provided for the years 2016–2028. Several growth factors and opportunities impacting various segments have been incorporated in the report.
On the basis of Indication, the market is divided into Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others. Open Angle Glaucoma held the largest share in 2020 and is projected to grow at a noteworthy CAGR within the forecast period.
Based on Drug Class, the market is divided into Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others. Prostaglandin Analogs attributed to the highest market share and is expected to grow at a significant CAGR from 2021 to 2028.
Global Glaucoma Medications Market: Indication Segment Analysis
- Open Angle Glaucoma
- Closed Angle Glaucoma
- Secondary Glaucoma
- Congenital Glaucoma
Global Glaucoma Medications Market: Drug Class Segment Analysis
- Prostaglandin Analogs
- Beta Blockers
- Alpha Agonist
- Carbonic Anhydrase Inhibitors
Regional Analysis: Preview
Based on the geography, the global Glaucoma Medications market is segmented into North America, Latin America, Asia
Pacific, Europe, and the Middle East & Africa. The report further segments
the regional study into key country-level markets from each region. This section
of the report provides a comprehensive review of the Glaucoma Medications market at the regional and country level. The report covers all the major developments
specific to Glaucoma Medications industry across
geographies and explains its impact on the market. The regional analysis
section also provides analysis of the impact of various factors such as
economies, industry competition, technological advancements, import-export
ratio, and raw material availability among others. The concentration of raw
material suppliers as well as market players in one specific region impacts the
global market scenario and the report covers exclusive information on the
same. Also, the report analyzes the
intensity of competition in each region and its influence on the growth of the
global Glaucoma Medications market.
Market Size, 2021 (USD Billion)
Global Glaucoma Medications Market: Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Southeast Asia
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of MEA
The global Glaucoma Medications market report provides an exhaustive competitive landscape to give a comprehensive synopsis of the global market. Major players in the Glaucoma Medications market are Laboratoires Thea, Actavis, APOTEX, GE Medical, Mylan, Taj Pharmaceuticals, Teva Pharmaceutical, Jamp Pharma, Greenstone, Mint Pharmaceuticals, SANDOZ, Bausch + Lomb, Fresenius, Sun Pharma, Laboratoire Riva, Pfizer, Novartis.. This section of the report will provide you extensive information on all key players based on business overview, product portfolio, marketing strategies, recent developments, financial performance, and geographical presence among others. Moreover, the report will also include extensive analysis on key strategies adopted by market players such as new product development/launch, merger & acquisitions, partnerships, collaborations & joint ventures, research & development, and regional expansion.
Frequently Asked Question
The global Glaucoma Medications valued at 7.51 Billion in 2020 and is expected to reach 10.76 Billion in 2028 growing at a CAGR of 4.6%.
The prominent players in the market are Laboratoires Thea, Actavis, APOTEX, GE Medical, Mylan, Taj Pharmaceuticals, Teva Pharmaceutical, Jamp Pharma, Greenstone, Mint Pharmaceuticals, SANDOZ, Bausch + Lomb, Fresenius, Sun Pharma, Laboratoire Riva, Pfizer, Novartis..
The market is project to grow at a CAGR of 4.6% between 2021 and 2028.
The driving factors of the Glaucoma Medications include
- The rising cases of glaucoma across the globe and new drug developments are expected to fuel the growth of the market during the forecast period.
- The technological advancement in treatment of glaucoma, and various pharmaceutical and biotechnological companies are investing in new product development for glaucoma is a factor driving the market.
North America was the leading regional segment of the Glaucoma Medications in 2020.